Terms: = Endocrine gland cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
4 results:
1. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
2. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract] [Full Text] [Related]
3. Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer.
Ishikawa T; Kokura S; Sakamoto N; Okayama T; Endo M; Tsuchiya R; Okajima M; Matsuyama T; Adachi S; Kamada K; Katada K; Uchiyama K; Handa O; Takagi T; Yagi N; Ando T; Uno K; Naito Y; Yoshikawa T
Int J Cancer; 2013 Sep; 133(5):1119-25. PubMed ID: 23420507
[TBL] [Abstract] [Full Text] [Related]
4. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract] [Full Text] [Related]